Folate Supplementation in Schizophrenia

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to examine factors potentially contributing to differences in blood folate, homocysteine or B12 levels between schizophrenia patients, to test the hypothesis that low folate is associated with negative symptoms, and to examine the efficacy of folate supplementation for reducing negative symptoms.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Alliance for Research on Schizophrenia and Depression
• Treatments: Folic Acid; Vitamin B Complex

Criteria

Inclusion Criteria:

1. Schizophrenia, any subtype

2. Ages 18-68

3. Male or female

4. A score at least a 3 (moderate or greater severity) on at least one of the SANS global assessment subscales, with the exception of the attention global assessment subscale

5. Stable antipsychotic dose for > 6 weeks

6. Capable of providing informed consent

Exclusion Criteria:

1. Unstable medical illness

2. Substance abuse

3. Megaloblastic anemia

4. Non-english speaking